All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, What is the real-world experience of relapsed/refractory AML treatment with venetoclax and hypomethylating agents (HMAs)?
What is the real-world experience of R/R AML treatment with venetoclax + HMAs?
In this video, DiNardo explains how the response rate of this regimen compares to other salvage chemotherapy options. She highlights that patients in the relapse setting have a higher chance of responding to this HMA regimen, including patients with diploid cytogenetics or MPN1, IDH1, and IDH2 mutations.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox